CG Oncology publishes Phase 3 bladder cancer trial results in Lancet
Tweet Send to a Friend
CG Oncology, Inc. (NASDAQ: CGON) announced the publication of results from its pivotal Phase 3 BOND-003 Cohort C trial in ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
